Allarity Therapeutics, Inc.

ALLR

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001860657

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $18.3M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	late filer, thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 30, 2026 229 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$0.97 2026-11-13; market equity $15.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell's sensitivity to a specific cancer therapeutic.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 94.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
required facts have no common fiscal period end						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	17.5%	(6.6%)	94.6	799	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 73.0					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(23.25)	(0.31)	76.3	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.13x	2.96x	69.7	825	2025-12-31
Growth and financing, sleeve percentile 18.5					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 1					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 3					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	7.9%	2.3%	35.3	693	2025-12-31
Net share issuance, one year	(7.0%)	2.4%	1.8	627	2026-03-30

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(27.6%)	(1.5%)	32
Distance from 52-week high	(46.1%)	(32.0%)	33
EBIT to enterprise value	(327.1%)	(1.8%)	3
Free cash flow yield	(97.2%)	(1.0%)	8
Book value to price	(0.15)	0.29	5
Sales to price	0.02	0.29	10
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(0.49)	(0.18)	32

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$14.1M
Operating cash flow, four quarters	-$13.2M
Months of runway	12.8
Days since last periodic filing	1 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$96,990

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$11.2M	2025-12-31	2026-03-30	10-K	26-010310
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.8M	2025-12-31	2026-03-30	10-K	26-010310
3	assets	us-gaap:Assets	$18.3M	2025-12-31	2026-03-30	10-K	26-010310
4	assets	us-gaap:Assets	$22.6M	2024-12-31	2026-03-30	10-K	26-010310
5	current assets	us-gaap:AssetsCurrent	$17.9M	2025-12-31	2026-03-30	10-K	26-010310
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.4M	2025-12-31	2026-03-30	10-K	26-010310
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$130.2M	2025-12-31	2026-03-30	10-K	26-010310
8	operating income	us-gaap:OperatingIncomeLoss	-$12.6M	2025-12-31	2026-03-30	10-K	26-010310
9	book equity	us-gaap:StockholdersEquity	$9.8M	2025-12-31	2026-03-30	10-K	26-010310
10	liabilities	us-gaap:Liabilities	$8.4M	2025-12-31	2026-03-30	10-K	26-010310
11	operating income	us-gaap:OperatingIncomeLoss	-$17.1M	2023-12-31	2025-03-31	10-K	25-010198
12	interest expense	us-gaap:InterestAndDebtExpense	$217,000	2023-12-31	2024-03-08	10-K	24-020864
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$320,000	2025-12-31	2026-03-30	10-K	26-010310
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$298,000	2024-12-31	2026-03-30	10-K	26-010310
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$9,000	2024-12-31	2025-03-31	10-K	25-010198
16	operating income	us-gaap:OperatingIncomeLoss	-$27.2M	2024-12-31	2026-03-30	10-K	26-010310
17	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$24.9M	2024-12-31	2026-03-30	10-K	26-010310
18	income tax	us-gaap:IncomeTaxExpenseBenefit	-$381,000	2024-12-31	2026-03-30	10-K	26-010310
19	current assets	us-gaap:AssetsCurrent	$22.3M	2024-12-31	2026-03-30	10-K	26-010310
20	current liabilities	us-gaap:LiabilitiesCurrent	$10.8M	2024-12-31	2026-03-30	10-K	26-010310
21	current assets	us-gaap:AssetsCurrent	$2.0M	2023-12-31	2025-03-31	10-K	25-010198
22	current liabilities	us-gaap:LiabilitiesCurrent	$14.2M	2023-12-31	2025-03-31	10-K	25-010198
23	assets	us-gaap:Assets	$11.9M	2023-12-31	2025-03-31	10-K	25-010198
24	assets	us-gaap:Assets	$14.5M	2022-12-31	2024-03-08	10-K	24-020864
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	15,818,980	2026-03-30	2026-03-30	10-K	26-010310
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	17,014,737	2025-03-31	2025-03-31	10-K	25-010198

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.